Pfizer By The Numbers: 800 R&D Job Cuts But At Least Two Dozen Phase III Projects By Year End
This article was originally published in The Pink Sheet Daily
Executive Summary
Research chief Mackay says Pfizer's research portfolio has been extensively reviewed by both internal and outside experts
You may also be interested in...
Pfizer Selects Sites for its Post-Merger Global R&D Network
Newly merged company will cut R&D staff by 15 percent, though timing is unclear.
Pfizer Selects Sites for its Post-Merger Global R&D Network
Newly merged company will cut R&D staff by 15 percent, though timing is unclear.
Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
A mega merger combining Pfizer and Wyeth would create a behemoth with combined sales of over $70 billion, build Pfizer's experience base in biotech, give Pfizer the substantial vaccine business it has been searching for and create billions in cost savings opportunities